Personalized Therapy in the Era of Precision Medicine: Guidance on Histology-Agnostic Therapies for the Community Multidisciplinary Oncology Team

Experts discuss histology-agnostic therapies for solid tumors, including key efficacy and safety data and guidance on appropriate molecular testing and adverse event management with an on-demand webcast and downloadable slideset from a live workshop series.

Share

Program Content

Activities

Histology-Agnostic Biomarkers in Solid Tumors
Personalized Therapy in the Era of Precision Medicine: Guidance on Histology-Agnostic Therapies for the Community Multidisciplinary Oncology Team
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 19, 2023

Activities

Histology-Agnostic Therapies
Personalized Therapy in the Era of Precision Medicine: Guidance on Histology-Agnostic Therapies for the Community Multidisciplinary Oncology Team
Video
Congratulations: You achieved a completion on 04/09/2022

Released: October 04, 2023

Expires: October 03, 2024

Faculty

cover img faculity

Razelle Kurzrock, MD

Professor
Medical College of Wisconsin
Milwaukee, Wisconsin

cover img faculity

Vivek Subbiah, MD

Chief, Early-Phase Drug Development
Sarah Cannon Research Institute
Nashville, Tennessee

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from Bayer HealthCare Pharmaceuticals Inc., Elevation Oncology, Merck Sharp & Dohme Corp., and Merus NV.

Bayer HealthCare Pharmaceuticals Inc.

Elevation Oncology

Merck Sharp & Dohme Corp.

Merus NV